Armata Pharmaceuticals Announces $35 Million Secured Credit Agreement with InnovivaPRNewsWire • 03/04/24
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressBusiness Wire • 02/29/24
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 NamesInvestorPlace • 01/10/24
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 11/01/23
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated GonorrheaBusiness Wire • 11/01/23
Innoviva Specialty Therapeutics Presents New Data on its Critical Care Antibiotic Therapy Portfolio at Infectious Disease Week (IDWeek) 2023Business Wire • 10/11/23
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in AdultsBusiness Wire • 09/18/23
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 08/02/23
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Innoviva, Inc. for Potential Breaches of Fiduciary Duty By Its Board of DirectorsPRNewsWire • 07/13/23
Armata Pharmaceuticals Announces New Financing and Leadership Transition to Accelerate Novel Bacteriophage TherapeuticsPRNewsWire • 07/11/23
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare ConferenceBusiness Wire • 06/06/23
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous UseBusiness Wire • 05/23/23
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious DiseasesBusiness Wire • 05/11/23
Innoviva Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressBusiness Wire • 05/09/23
Sulbactam-Durlobactam Unanimously Recommended for Approval by FDA Advisory CommitteeBusiness Wire • 04/17/23
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted AntibioticBusiness Wire • 03/13/23